SAB Biotherapeutics, Inc. (SABS) stock
SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.96−0.12 (-3.90%)
Close on Nov 13, 2026Market cap $269.32MP/E –Yield –
SAB Biotherapeutics cash
Cash and short-term investments held at the end of each period.
SAB Biotherapeutics's cash was $104.05M at Sep 30, 2026. For fiscal 2025 it was $96.59M, up 365.3% from the year before. The highest annual figure on record is $96.59M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $96.59M | +365.3% |
| FY2024 | Dec 31, 2024 | $20.76M | -63.3% |
| FY2023 | Dec 31, 2023 | $56.57M | +275.9% |
| FY2022 | Dec 31, 2022 | $15.05M | -61.9% |
| FY2021 | Dec 31, 2021 | $39.55M | +213.6% |
| FY2020 | Dec 31, 2020 | $12.61M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $104.05M | -6.2% |
| Q2 FY2026 | Jun 30, 2026 | $102.63M | +1696.3% |
| Q1 FY2026 | Mar 31, 2026 | $107.39M | +735.7% |
| Q4 FY2025 | Dec 31, 2025 | $96.59M | +365.3% |
| Q3 FY2025 | Sep 30, 2025 | $110.88M | +264.7% |
| Q2 FY2025 | Jun 30, 2025 | $5.71M | -84.7% |
| Q1 FY2025 | Mar 31, 2025 | $12.85M | -70.8% |
| Q4 FY2024 | Dec 31, 2024 | $20.76M | -63.3% |
| Q3 FY2024 | Sep 30, 2024 | $30.40M | +1153.4% |
| Q2 FY2024 | Jun 30, 2024 | $37.33M | +380.1% |
| Q1 FY2024 | Mar 31, 2024 | $44.06M | +237.3% |
| Q4 FY2023 | Dec 31, 2023 | $56.57M | +275.9% |
| Q3 FY2023 | Sep 30, 2023 | $2.43M | -70.9% |
| Q2 FY2023 | Jun 30, 2023 | $7.77M | -53.2% |
| Q1 FY2023 | Mar 31, 2023 | $13.06M | -41.7% |
| Q4 FY2022 | Dec 31, 2022 | $15.05M | -61.9% |
| Q3 FY2022 | Sep 30, 2022 | $8.33M | -22.5% |
| Q2 FY2022 | Jun 30, 2022 | $16.62M | +62.4% |
| Q1 FY2022 | Mar 31, 2022 | $22.41M | +11.3% |
| Q4 FY2021 | Dec 31, 2021 | $39.55M | +213.6% |
| Q3 FY2021 | Sep 30, 2021 | $10.75M | – |
| Q2 FY2021 | Jun 30, 2021 | $10.23M | – |
| Q1 FY2021 | Mar 31, 2021 | $20.13M | – |
| Q4 FY2020 | Dec 31, 2020 | $12.61M | – |
See a number that looks wrong?